MedTrace Logo

Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

NCT01008852 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2013-12-03

No results posted yet for this study

Summary

This study is designed to evaluate the safety and efficacy of a dose and dosage regimen of SBI-087 in seropositive patients with active Rheumatoid Arthritis, who are on a stable dose of methotrexate.

Conditions

  • Active Rheumatoid Arthritis

Interventions

DRUG

SBI-087

200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate

DRUG

SBI-087

200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate

DRUG

SBI-087

200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate

DRUG

SBI-087

200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate

DRUG

Placebo

Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate

Sponsors & Collaborators

  • Emergent Product Development Seattle LLC

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-09-30
Completion
2013-07-31

Countries

  • United States
  • Argentina
  • Canada
  • Chile
  • Hungary
  • Japan
  • Mexico
  • Poland
  • Serbia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01008852 on ClinicalTrials.gov